Home > Healthcare > Biotechnology > Biotechnology R&D > Cell Lysis & Disruption Market

Cell Lysis & Disruption Market Size

  • Report ID: GMI7723
  • Published Date: Dec 2023
  • Report Format: PDF

Cell Lysis & Disruption Market Size

Cell Lysis & Disruption Market size was valued USD 5.1 billion in 2023 and is expected to reach USD 10.9 billion by 2032 growing at a CAGR of 8.6% over the analysis period. High growth can be attributed to the expanding biopharmaceutical industry that relies on cell lysis and disruption techniques to produce therapeutic proteins, monoclonal antibodies, and vaccines.

 

Also, the growing interest in precision medicine and advancements in genomics research has further increased the demand for cell lysis and disruption technologies. Moreover, growing investments by several organizations, including government and private, towards the research and development related to biotechnological processes are further expected to drive the market. Thus, as the life sciences industry continues to evolve, the cell lysis and disruption market are expected to witness sustained growth.

 

Cell lysis and disruption refer to the process of breaking open or disrupting the cell membrane of biological cells, releasing the cellular contents. This is a crucial step in various biological and biochemical applications, such as protein purification & isolation, DNA or RNA isolation, and the production of cellular products.

 

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global cell lysis & disruption industry size was valued USD 5.1 billion in 2023 and is expected to reach USD 10.9 billion by 2032, attributed to the expanding biopharmaceutical sector with focus on producing therapeutic proteins, monoclonal antibodies, and vaccines.

The reagent-based segment is expected to account for a revenue of USD 5.9 billion by 2032, these methods offer a cost-effective, simplified, and user-friendly approach, eliminating the need for complex equipment and specialized skills.

In 2023, North America held a significant market share of 37.9% and is anticipated to present lucrative opportunities over 2023-2032, backed by a robust infrastructure supporting cutting-edge R&D, a thriving biotechnology industry, and a well-established healthcare ecosystem.

Thermo Fisher Scientific, Inc., Merck KGaA, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., QIAGEN N.V., Danaher Corporation, Miltenyi Biotec, Claremont BioSolutions, LLC, and IDEX.

Cell Lysis & Disruption Market Scope

Buy Now


Premium Report Details

  • Base Year: 2023
  • Companies covered: 13
  • Tables & Figures: 532
  • Countries covered: 19
  • Pages: 250
 Download Free Sample